

10690 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

62. Ellis, J. L., D. Pickering and W. Trillwood, "Digitalisation of Infants," The Lancet, p. 325, Aug. 12, 1972.
63. Kolendorf, K., N. J. B. Christiansen, L. Siersback-Nielsen and J. M. Hansen, "Serum-digoxin After Dosage Regimen Based on Body-weight and Renal Function," The Lancet, p. 326, Aug. 12, 1972.
64. Kuno-Sakai, H., H. Sakai and S. E. Ritzmann, "Interference of Digitoxin with the Radioimmunoassay of Digoxin," The Lancet, p. 326-327, Aug. 12, 1972.
65. Shaw, T. R. D., M. R. Howard and J. Hamer, "Variation in the Biological Availability of Digoxin," The Lancet, pp. 303-307, Aug. 12, 1972.
66. "The Bioavailability of Digoxin," The Lancet (editorial), pp. 311-312, Aug. 12, 1972.
67. Binnion, P. F. and M. McDermott, "Bioavailability of Digoxin," The Lancet (letters to the editor), p. 592, Sept. 16, 1972.
68. "Bioavailability and Digoxin," New Zealand Medical Journal (editorial), 76:203, Sept. 1972.
69. Graser, E. J., R. H. Leach and J. W. Poston, "Bioavailability of Digoxin," The Lancet, p. 541, Sept. 9, 1972.
70. Stewart, M. J. and E. Simpson, "New Formulation of Lanoxin; Expected Plasma Levels of Digoxin," The Lancet, p. 541, Sept. 9, 1972.
71. Butler, V. P., Jr., "Practical Aspects of Immunological Assays," Resident and Staff Physician, pp. 46-55, Sept. 1972.